Adenosine and Digoxin

Cardiac Electrophysiology: Fourth Edition

Volumn , Issue , 2004, Pages 942-949

  DiMarco, John P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69349105572     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-7216-0323-8/50105-6     Document Type: Chapter

References (43)

1. Shyrock JC, Belardinelli L Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology. Am J Cardiol 1997, 79(12A):2-10.
2. Mubagwa K, Flameng W Adenosine, adenosine receptors and myocardial protection: An updated overview. Cardiovasc Res 2001, 52:25-39.
3. Mangrum JM, DiMarco JP Acute and chronic pharmacologic management of supraventricular tachyarrhythmias. Cardiovascular Therapeutics 2002, 423-444. WB Saunders, Philadelphia. 2nd ed. E.M. Antman (Ed.).
4. Bertolet BD, Eagle DA, Conti JB, et al. Bradycardia after heart transplantation: Reversal with theophylline. J Am Coll Cardiol 1997, 29:470-471.
5. Wang D, Shyrock JC, Belardinelli L Cellular basis for the negative dromotropic effect of adenosine on rabbit single atrioventricular nodal cells. Circ Res 1996, 78:697-706.
6. 1 adenosine receptor agonist (CVT-510) with diltiazem for slowing of AV nodal conduction in guinea pig. Br J Pharmacol 1999, 126:137-146.
7. 1 agonist (CVT-510) on atrioventricular nodal conduction in humans. J Cardiovasc Pharmacol Ther 2001, 6:237-245.
8. DiMarco JP, Sellers TD, Berne RM, et al. Adenosine: Electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 1983, 68:1254-1263.
9. Kou WH, Man KC, Goyal R, et al. Interaction between autonomic tone and the negative dromotropic effect of adenosine in humans. Pacing Clin Electrophysiol 1999, 22:1792-1796.
10. Souza JJ, Zivin A, Fleming M, et al. Differential effect of adenosine on anterograde and retrograde fast pathway conduction in patients with atrioventricular nodal reentrant tachycardia. J Cardiovasc Electrophysiol 1998, 9:820-824.
11. Curtis AB, Belardinelli L, Woodard DA, et al. Induction of atrioventricular node reentrant tachycardia with adenosine: Differential effect of adenosine on fast and slow atrioventricular node pathways. J Am Coll Cardiol 1997, 30:1778-1784.
12. Tebbenjohanns J, Schumacher B, Pfeiffer D, et al. Dose and ratedependent effects of adenosine on atrial action potential duration in humans. J Interv Card Electrophysiol 1997, 1:39-40.
13. Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation 1999, 99:1034-1040.
14. Biaggioni I, Olafsson B, Robertson RM, et al. Cardiovascular and respiratory effects of adenosine in conscious man. Evidence for chemoreceptor activation. Circ Res 1987, 61:779-786.
15. Leppo J Comparison of pharmacologic stress agents. J Nucl Cardiol 1996, 3:S22-S26.
16. DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: Dose ranging and comparison with verapamil in placebo-controlled, multicenter trials. Ann Intern Med 1990, 113:104-110.
17. Strickberger SA, Man KC, Daoud EG, et al. Adenosine-induced atrial arrhythmia: A prospective analysis. Ann Intern Med 1997, 127:417-422.
18. Markowitz SM, Stein KM, Mittal S, et al. Differential effects of adenosine on focal and macroreentrant atrial tachycardia. J Cardiovasc Electrophysiol 1999, 10:489-492.
19. Lerman BB, Stein KM, Markowitz SM Adenosine-sensitive ventricular tachycardia: A conceptual approach. J Cardiovasc Electrophysiol 1996, 7:559-569.
20. αi2. J Clin Invest 1998, 101:2862-2868.
21. o'Rourke DJ, Palac RT, Schindler JT, et al. The clinical utility of adenosine in difficult to diagnose tachyarrhythmias. Clin Cardiol 1999, 22:633-636.
22. Bertolet BD, Hill JA Adenosine: Diagnostic and therapeutic uses in cardiovascular medicine. Chest 1993, 104:1860-1871.
23. Burnett D, Abi-Samra F, Vacek JL Use of intravenous adenosine as a noninvasive diagnostic test for sick sinus syndrome. Am Heart J 1999, 137:377-380.
24. Shen WK, Hamill SC, Munger TM, et al. Adenosine: Potential modulator for vasovagal syncope. J Am Coll Cardiol 1996, 28:146-154.
25. Mittal S, Stein KM, Markowitz SM, et al. Induction of neurally mediated syncope with adenosine. Circulation 1999, 99:1318-1324.
26. Stafford RS, Robson DC, Misra B, et al. Rate control and sinus rhythm maintenance in atrial fibrillation: National trends in medication use, 1980-1996. Arch Intern Med 1998, 158:2144-2148.
27. The Digital Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533.
28. Eichhorn EJ, Gheorghiade M Digoxin. Prog Cardiovasc Dis 2002, 44:251-266.
29. Duytschaever MF, Garratt CJ, Allessie MA Profibrillatory effects of verapamil but not of digoxin in the goat model of atrial fibrialltion. J Cardiovasc Electrophysiol 2000, 11:1375-1385.
30. Tieleman RG, Blaauw Y, Van Gelder I, et al. Digoxin delays recovery from tachycardia-induced electrical remodeling of the atria. Circulation 1999, 100:1836-1842.
31. Sticherling C, Oral H, Horrocks J, et al. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation 2000, 102:2503-2508.
32. Hornestam B, Held P, Edvardsson N Effects of digoxin on the electrocardiogram in patients with acute atrial fibrillation-a randomized, placebo-controlled study. Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Clin Cardiol 1999, 22:96-102.
33. Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002, 72:202-219.
34. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
35. Digitalis in Acute Atrial Fibrillation Trial Group Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 1997, 18:649-654.
36. Jordaens L, Trouerbach J, Calle P, et al. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J 1997, 18:643-648.
37. Farshi R, Kistner D, Sarma JSM, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens. J Am Coll Cardiol 1999, 33:304-310.
38. Murgatroyd FD, Gibson SM, Baiyan X, et al. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation 1999, 99:2765-2770.
39. Marik PE, Fromm L A case series of hospitalized patients with elevated digoxin levels. Am J Med 1998, 105:110-115.
40. Abad-Santos F, Carcas AJ, Ibanez C, et al. Digoxin level and clinical manifestations as determinants in the diagnosis of digoxin toxicity. Ther Drug Monit 2000, 22:163-168.
41. Gittelman MA, Stephan M, Perry H Acute pediatric drug ingestion. Pediatr Emerg Care 1999, 15:359-362.
42. Ward SB, Sjostrom L, Ujhelyi MR Comparison of the pharmacokinetics and in vivo bioaffinity of DigiTAb versus Digibind. Ther Drug Monit 2000, 22:599-607.
43. Zdunek M, Mitra A, Mokrzycki MH Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: Timing is important for maximizing clearance. Am J Kidney Dis 2000, 36:177-183.